Apellis pharmaceuticals, inc. (APLS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Dec'16
Assets
Current assets:
Cash and cash equivalents

417,900

351,985

433,994

289,100

288,246

176,267

220,640

253,839

152,930

175,643

13,135

24,863

Marketable securities

228,800

-

-

-

-

-

-

-

-

-

-

-

Refundable research and development credit

-

-

-

1,950

1,755

-

1,364

1,996

1,828

1,297

2,243

1,347

Prepaid assets

22,806

19,802

14,742

13,977

20,509

24,333

16,846

10,857

8,121

5,059

-

1,132

Restricted cash

1,000

-

-

-

-

-

-

-

-

-

-

-

Other current assets

1,891

1,308

2,457

3,355

15

1,837

81

7

205

14

3,653

25

Total current assets

672,407

373,095

451,194

308,412

310,527

202,439

238,932

266,701

163,086

182,015

19,032

27,368

Non-current Assets:
Right-of-use assets

13,715

14,110

13,332

6,644

6,621

-

-

-

-

-

-

-

Property and equipment, net

1,972

1,655

1,592

1,439

1,041

977

-

-

-

-

-

-

Other assets

845

385

236

207

162

116

212

116

116

116

108

64

Total assets

688,939

389,245

466,356

316,704

318,353

203,533

239,145

266,817

163,203

182,131

19,141

27,433

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

3,078

8,361

11,836

13,811

11,916

10,254

5,468

5,133

4,585

3,663

4,001

2,547

Accrued expenses

44,930

54,783

30,431

20,229

7,342

5,103

10,565

5,121

2,709

2,890

2,936

1,091

Current portion of long-term-debt

-

-

-

-

-

1,666

-

-

-

-

-

-

Current portion of right of use liabilities

2,732

2,609

2,304

1,549

1,127

-

-

-

-

-

-

-

Total current liabilities

50,740

65,753

44,572

35,591

20,386

17,024

16,034

10,254

7,294

6,553

6,937

3,638

Long-term liabilities:
Convertible senior notes

144,561

142,567

140,614

-

-

-

-

-

-

-

-

-

Development derivative liability

223,245

134,839

130,103

109,840

60,736

-

-

-

-

-

-

-

Term loan facility

-

-

-

-

-

18,722

20,270

20,143

20,015

19,806

-

-

Promissory note

-

-

-

6,693

6,673

6,655

6,636

6,618

6,600

6,583

-

-

Operating lease liabilities

11,396

11,857

-

-

-

-

-

-

-

-

-

-

Right-of-use liabilities

-

-

11,255

5,243

5,566

-

-

-

-

-

-

-

Other liabilities

-

-

250

250

234

158

-

-

-

-

-

-

Common stock warrant liability

-

-

-

-

-

-

250

250

250

244

-

-

Total liabilities

429,942

355,016

326,795

157,617

93,598

42,560

43,190

37,265

34,160

33,188

-

3,638

Stockholders' equity:
Preferred stock, $0.0001 par value; 10.0 million shares authorized, and zero shares issued and outstanding at March 31, 2020 and December 31, 2019

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.0001 par value; 200.0 million shares authorized at March 31, 2020 and December 31, 2019; 75.4 million shares issued and outstanding at March 31, 2020, and 63.9 million shares issued and outstanding at December 31, 2019

7

6

6

6

6

5

5

5

5

5

0

0

Additional paid in capital

1,008,275

615,850

608,015

557,632

552,209

437,855

435,915

433,880

300,037

298,201

31,407

29,996

Accumulated other comprehensive income/(loss)

1,010

-154

-205

-121

-120

-122

339

-

-

-

-

-

Accumulated deficit

-750,295

-581,473

-468,255

-398,430

-327,340

-276,765

-240,306

-204,334

-170,999

-149,263

-131,007

-98,257

Total stockholders' equity

258,997

34,229

139,561

159,086

224,754

160,972

195,954

229,552

129,042

148,942

12,203

23,794

Total liabilities and stockholders' equity

688,939

389,245

466,356

316,704

318,353

203,533

239,145

266,817

163,203

182,131

19,141

27,433